Production (Stage)
Leap Therapeutics, Inc.
LPTX
$0.393
-$0.0022-0.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.47% | 13.81% | 9.70% | -45.64% | -10.87% |
| Total Depreciation and Amortization | -- | -- | 100.00% | -2,100.00% | 25.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.10% | 31.75% | -7.28% | 14.81% | 225.54% |
| Change in Net Operating Assets | 79.38% | -256.58% | -77.48% | 262.84% | -284.42% |
| Cash from Operations | 6.65% | 0.56% | -14.11% | 11.89% | -49.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.62% | -- | -100.00% | 137,827.59% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 97.71% | -- | -- |
| Cash from Financing | -158.65% | 257.58% | -100.18% | 127,889.66% | -- |
| Foreign Exchange rate Adjustments | 103.01% | -1,760.00% | -91.07% | 147.66% | -183.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.66% | 0.52% | -166.46% | 249.84% | -55.66% |